Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants

Abdrakhmanov A. Shaimerdinova A. Suleimen Z. Abildinova S. Albayev R. Tuyakova G. Rib E. Beysenbayeva A. Kabduyeva G. Bekbossynova M.
January-December 2024 SAGE Publications Ltd

Therapeutic Advances in Cardiovascular Disease
2024 #18

Atrial fibrillation (AF) accounts for 40% of all cardiac arrhythmias and is associated with a high risk of stroke and systemic thromboembolic complications. Dabigatran, rivaroxaban, apixaban, and edoxaban are direct oral anticoagulants (DOACs) that have been proven to prevent stroke in patients with non-valvular AF. This review summarizes the pharmacokinetics, pharmacodynamics, and drug interactions of DOACs, as well as new data from pharmacogenetic studies of these drugs. This review is aimed at analyzing the scientific literature on the gene polymorphisms involved in the metabolism of DOACs. We searched PubMed, Cochrane, Google Scholar, and CyberLeninka (Russian version) databases with keywords: ‘dabigatran’, ‘apixaban’, ‘rivaroxaban’, ‘edoxaban’, ‘gene polymorphism’, ‘pharmacogenetics’, ‘ABCB1’, ‘CES1’, ‘SULT1A’, ‘ABCG2’, and ‘CYP3A4’. The articles referred for this review include (1) full-text articles; (2) study design with meta-analysis, an observational study in patients taking DOAC; and (3) data on the single-nucleotide polymorphisms and kinetic parameters of DOACs (plasma concentration), or a particular clinical outcome, published in English and Russian languages during the last 10 years. The ages of the patients ranged from 18 to 75 years. Out of 114 reviewed works, 24 were found eligible. As per the available pharmacogenomic data, polymorphisms affecting DOACs are different. This may aid in developing individual approaches to optimize DOAC pharmacotherapy to reduce the risk of hemorrhagic complications. However, large-scale population studies are required to determine the dosage of the new oral anticoagulants based on genotyping. Information on the genetic effects is limited owing to the lack of large-scale studies. Uncovering the mechanisms of the genetic basis of sensitivity to DOACs helps in developing personalized therapy based on patient-specific genetic variants and improves the efficacy and safety of DOACs in the general population.

ABCB1 , ABCG2 , apixaban , CES1 , CYP3A4 , dabigatran , edoxaban , gene polymorphism , non-valvular atrial fibrillation , rivaroxaban , SULT1A

Text of the article Перейти на текст статьи

National Research Cardiac Surgery Center, Turan Ave 38, Astana, 010000, Kazakhstan
Medical University of Astana, Astana, Kazakhstan
Hospital of the Medical Center of the Administration of the President of the Republic of Kazakhstan, Astana, Kazakhstan

National Research Cardiac Surgery Center
Medical University of Astana
Hospital of the Medical Center of the Administration of the President of the Republic of Kazakhstan

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026